MDGL
Price
$229.32
Change
+$7.34 (+3.31%)
Updated
Dec 5, 10:20 AM EST
79 days until earnings call
SAGE
Price
$20.52
Change
-$0.32 (-1.54%)
Updated
Dec 5, 9:46 AM EST
79 days until earnings call
Ad is loading...

Compare trend and price MDGL vs SAGE

Header iconMDGL vs SAGE Comparison
Open Charts MDGL vs SAGEBanner chart's image
Madrigal Pharmaceuticals
Price$229.32
Change+$7.34 (+3.31%)
Volume$400
CapitalizationN/A
Sage Therapeutics
Price$20.52
Change-$0.32 (-1.54%)
Volume$100
CapitalizationN/A
View a ticker or compare two or three
MDGL vs SAGE Comparison Chart

Loading...

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
VS
MDGL vs. SAGE commentary
Dec 05, 2023

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a Buy and SAGE is a Buy.

COMPARISON
Comparison
Dec 05, 2023
Stock price -- (MDGL: $221.99 vs. SAGE: $20.84)
Brand notoriety: MDGL and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 88% vs. SAGE: 77%
Market capitalization -- MDGL: $3.9B vs. SAGE: $1.15B
MDGL [@Biotechnology] is valued at $3.9B. SAGE’s [@Biotechnology] market capitalization is $1.15B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileSAGE’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • SAGE’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than SAGE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 6 TA indicator(s) are bullish while SAGE’s TA Score has 5 bullish TA indicator(s).

  • MDGL’s TA Score: 6 bullish, 4 bearish.
  • SAGE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than SAGE.

Price Growth

MDGL (@Biotechnology) experienced а +12.51% price change this week, while SAGE (@Biotechnology) price change was +9.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +15.58%. For the same industry, the average monthly price growth was +27.91%, and the average quarterly price growth was +26.95%.

Reported Earning Dates

MDGL is expected to report earnings on Feb 22, 2024.

SAGE is expected to report earnings on Feb 22, 2024.

Industries' Descriptions

@Biotechnology (+15.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for MDGL with price predictions.
OPEN
A.I.dvisor published
a Summary for SAGE with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
MDGL($3.9B) has a higher market cap than SAGE($1.15B). MDGL YTD gains are higher at: -23.518 vs. SAGE (-45.359). MDGL has higher annual earnings (EBITDA): -336.4M vs. SAGE (-656.8M). SAGE has more cash in the bank: 876M vs. MDGL (232M). SAGE has less debt than MDGL: SAGE (6.97M) vs MDGL (117M). SAGE has higher revenues than MDGL: SAGE (11.3M) vs MDGL (0).
MDGLSAGEMDGL / SAGE
Capitalization3.9B1.15B340%
EBITDA-336.4M-656.8M51%
Gain YTD-23.518-45.35952%
P/E RatioN/A2.85-
Revenue011.3M-
Total Cash232M876M26%
Total Debt117M6.97M1,679%
FUNDAMENTALS RATINGS
MDGL vs SAGE: Fundamental Ratings
MDGL
SAGE
OUTLOOK RATING
1..100
307
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
77100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
3564
P/E GROWTH RATING
1..100
10093
SEASONALITY SCORE
1..100
7510

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (55) in the Pharmaceuticals Other industry is somewhat better than the same rating for MDGL (96). This means that SAGE’s stock grew somewhat faster than MDGL’s over the last 12 months.

MDGL's Profit vs Risk Rating (77) in the Pharmaceuticals Other industry is in the same range as SAGE (100). This means that MDGL’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as MDGL (100). This means that SAGE’s stock grew similarly to MDGL’s over the last 12 months.

MDGL's Price Growth Rating (35) in the Pharmaceuticals Other industry is in the same range as SAGE (64). This means that MDGL’s stock grew similarly to SAGE’s over the last 12 months.

SAGE's P/E Growth Rating (93) in the Pharmaceuticals Other industry is in the same range as MDGL (100). This means that SAGE’s stock grew similarly to MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLSAGE
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
69%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
74%
Declines
ODDS (%)
Bearish Trend 27 days ago
81%
Bearish Trend 20 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WQDGX9.750.03
+0.31%
WCM Quality Dividend Growth Investor
DYGAX13.17N/A
N/A
Meeder Dynamic Allocation Adviser
MMLRX13.16N/A
N/A
MassMutual Select TRP Large Cap Blend I
PEQYX14.77-0.06
-0.40%
Putnam Focused International Equity Y
DFETX17.19-0.10
-0.58%
DFA Emerging Markets II